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ABSTRACT
Antimicrobial Stewardship Programs (ASPs) are being implemented worldwide to optimize antimicro-
bial therapy, and thereby improve patient safety and quality of care. Additionally, this should counteract
resistance development. It is, however, vital that correct and timely diagnostics are performed in
parallel, and that an institution runs a well-organized infection prevention program. Currently, there
is no clear consensus on which interventions an ASP should comprise. Indeed this depends on the
institution, the region, and the patient population that is served. Different interventions will lead to
different effects. Therefore, adequate evaluations, both clinically and financially, are crucial. Here, we
provide a general overview of, and perspective on different intervention strategies and methods to
evaluate these ASP programs, covering before mentioned topics. This should lead to a more consistent
approach in evaluating these programs, making it easier to compare different interventions and studies
with each other and ultimately improve infection and patient management.
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1. Introduction
Antimicrobial resistance is a growing problem. One of the
major drivers of this disconcerting development is inadequate
use of antimicrobials, both in health-care centers and out-
patient settings [1], as well as in livestock [2]. The so-called
One Health approach targets resistance development on all
the before-mentioned levels. Such a broad approach is con-
sidered crucial, in order to effectively minimize the worldwide
health-care antimicrobial resistance threat [3]. Part of this
approach is improving the usage of antimicrobials in health-
care centers and outpatient settings, which in turn helps
reducing resistance development [4]. Antimicrobial
Stewardship Programs (ASPs) are being hailed as a solution
to improve antimicrobial therapies and thus result in a better
patient outcome and safety. Different national and interna-
tional guidelines are available for hospitals, long-term care
facilities, and general practitioners [5–7]. There is, however,
no clear consensus on the impact of different interventions
[8,9]. Effects (clinical and financial) in specific settings or
patient populations are difficult to compare and/or evaluate.
Some interventions might even be redundant or counterpro-
ductive, although in general, published results are often favor-
able [8,9]. This inconclusiveness necessitates performing
scientifically sound (cost-)effectiveness studies on ASP inter-
ventions [10]. There are multitudes of methods to evaluate
several interventions, but in general, they lack uniformity [10–
12]. In this review, we will discuss stewardship in general, its
(pre)requisites and the main interventions and their
approaches for evaluation, thereby giving a general and up-
to-date overview.
2. Importance of a broad stewardship program
The term ‘antimicrobial stewardship’ has been coined roughly
20 years ago [13]. Stewardship programs are now being imple-
mented worldwide and hundreds of articles are published
yearly [14]. As it became clear that inadequate antimicrobial
use (prophylactic and therapeutic) contributes to resistance
development, improving antimicrobial usage became a focus
for many health-care institutions, using a subset of different
interventions [5,8]. However, it is often overlooked that redu-
cing resistance rates should not be the primary goal. The
ultimate goal is to improve clinical outcome and patient safety
by providing optimal patient care. Patients should be the main
focus and they have important questions related to infectious
problems: (1) How can I be protected from a (resistant) infec-
tion? (2) Do I have an infection, and if yes, what is causing it?
(3) What is the optimal treatment to cure it? Answering these
questions requires a broader approach than just an ASP and
also entails that certain requirements are met. Besides imple-
menting an ASP, an Infection prevention Stewardship Program
should be present to ensure that other patients do not get
infected by pertinent (resistant) pathogens, which are often
easy transmissible. Furthermore, optimal and timely diagnos-
tics that can adequately and rapidly diagnose the patient’s
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problems are vital (Diagnostic Stewardship Program). Only if
all three aspects are covered – optimal treatment, prevention,
and diagnostics (an integrated, Antimicrobial, Infection pre-
vention & Diagnostic [AID] stewardship program) – and all
involved stakeholders have the necessary meta-competence
(meaning a broad understanding of all relevant above-men-
tioned aspects), health-care centers can optimally treat infec-
tious patients and tackle the development of antimicrobial
resistance [15,16]. Because patient transfers between institu-
tions are also pathogen transfers [17], these three aspects
should not only be covered within one local center, but in a
(regional) health-care network. This entails close collaboration
of all health-care facilities (i.e. hospitals, but also general prac-
tices and long-term care facilities) within a clearly defined
region [18]. Harmonization of guidelines and practices can
be a first start regarding this aspect [19]. In the near future,
such an integrated AID approach should lead to a more
personalized treatment plan, which is optimally adapted to
the specifics of each single patient.
3. Importance of diagnostics
It is thus important that adequate diagnostics are per-
formed on time and provide rapid results to have impact
on patient care [20]. Ideally, results, including resistance
patterns, should be available before the patient is started
on antimicrobial treatment. Three parameters influence the
value of diagnostic tests: quality, cost, and time. Overall, the
sensitivity and specificity of new commercial and often
multiplex-based molecular, point-of-care (POC) assays
approach the quality of laboratory developed tests. In this
situation, lower costs and/or shorter turnaround times
become the main drivers for increased value. From a man-
agerial point of view, we introduced the euro-hour concept,
comparable with kilowatt-hour, to easily visualize the
impact of both parameters [16]. In this concept, the costs
of a test are multiplied by the turnaround time and there-
fore represent the impact of implementing a POC test. POC
tests can only have an impact on antimicrobial therapy and
patient management if results are timely available, inter-
preted, and followed-up by a medical specialist [21,22].
When implemented, it increases the probability of a correct
(preliminary) diagnosis – including the reduced need for
further diagnostics, streamline antimicrobial treatment
sooner if needed (thereby also minimizing the risk for
toxicity), and improve infection prevention measurements.
In the field of oncology, this so-called theragnostics
approach is under continuous development during recent
years and it would be a powerful tool in personalized
infection management as well [15,16]. Examples of POC
tests or rapid diagnostics (e.g. multiplex PCR and matrix-
assisted laser desorption/ionization time-of-flight mass spec-
trometry) already implemented for ASPs are: methicillin-
resistant Staphylococcus aureus (MRSA) screening and test-
ing [23–25]; resistance screening [26]; the use in septic/
bacteremic patients [27–29]; use of biomarkers (of which
procalcitonin probably shows the most promising results)
[30–33]; and with viral infections, such as for respiratory
illness [19,34].
4. Basics of ASPs
Often ASP interventions are subdivided into three groups: the
front-end approach, the back-end approach, and supplemental
interventions. Front-end interventions focus on the start of
empirical therapy such as pre-analytic consultations and guide-
lines for (empiric) therapy. Back-end interventions focus on
optimization of therapy after, for example, 2 or 3 days. For
example, an intravenous (IV)-to-oral switch promotion, de-esca-
lation, or timely stop of therapy, as appropriate. Finally, there
are interventions that supplement an ASP such as using resis-
tance data to keep local guidelines up to date and the avail-
ability of educational programs [5]. The evaluation of the
program is also an important aspect of the latter group. Such
a different array of interventions implies that the timeline of
impact of an ASP varies broad, with effects on the short-,
middle-, and long-term (see Figure 1 for a schematic overview).
An ASP should focus on improving patient care and safety,
by increasing appropriateness of all antimicrobial use (i.e.
prophylactics, empiric therapy, and directed therapy). When
looking at prophylactic antimicrobials, there are special cases
like Selective Digestive (or Intestinal) Decontamination (SDD)
and Selective Oropharyngeal Decontamination (SOD). SDD
and SOD are generally implemented at intensive care units
(ICUs), and thus are often not part of a standard ASP. They are,
however, important forms of antimicrobial use that can influ-
ence resistance development and will impact overall policy of
antimicrobial usage. It is thus imperative to take these inter-
ventions into account when implementing (and evaluating)
antimicrobial use and/or intervention strategies [35,36].
Figure 1. Schematic overview of expected timeline of impact of a subset of ASP different aspects.
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5. Unresolved issues with evaluating ASPs
The recent systematic Cochrane review on interventions to
improve antimicrobial therapy systematically looked at all stu-
dies describing one or more interventions and evaluated their
quality and strength of evidence [8]. This review mainly
focuses on the clinical effects. One of the main conclusions
that can be drawn from the review is the lack of quality of
evaluations reported. This is exemplified by the fact that the
majority of the studies could not be included [8]. A recent
highly comprehensive systematic review and meta-analysis of
14 different antimicrobial stewardship objectives found similar
results, albeit generally with a low quality of evidence [9].
Financial effects are equally important. In 2015, two reviews
on financial evaluations of ASP studies were published. Both
conclude that ASPs are evaluated inconsistently and often
even poorly, making it almost impossible to compare studies
with another [37,38]. Keeping these results in mind, we will
provide a general overview of the different methods to eval-
uate ASP interventions both clinically and financially (leaving
out structural and process-focused aspects). Furthermore, we
will mention some pros and cons for each method.
6. Different methods of evaluating ASPs
Randomized controlled trials (RCTs) are considered as the gold
standard and most preferable type of study. However, they are
often less suitable for antimicrobial intervention studies, due
to logistics, ethics, and costs. Nevertheless, in recent years
there were a couple of examples looking at ASP interventions
in a randomized controlled manner [39,40]. The large majority
of published evaluations are however observational studies
(e.g. case-control studies, interrupted time series [ITS] analyses,
etc.) [8,9,14]. For these studies, comparable cohorts of patients
are a major source for bias. This can be even more influenced
by changes over time, because the control period is usually
several years prior to the intervention period.
With regard to economic evaluations, the preferred method
would be to do a cost-effectiveness/-utility study from a soci-
etal perspective [41]. Generally speaking, the level of expertise
and the time required to do such an analysis are often too
scarce to be practically accessible. In practice, this has led to
the fact that economic evaluations performed on ASPs are
often cost-minimization analyses [37]. Finally, of relevance is
the fact that ASPs are implemented on specific wards and/or
for specific patient groups (e.g. ICUs, long-term care facilities,
septic patients, pediatric patients, and MRSA infections). This
makes comparability difficult and it is therefore essential to
mention in detail the patient characteristics, as well as the
setting of implementation.
7. Clinical outcome measures
The most important goal for an ASP should be to improve
quality of patient care. A number of different measures are
used that describe some aspects of clinical outcomes. Most
important are mortality rates. In general, most studies that
evaluate mortality conclude it is not compromised and that
an ASP is thus a safe intervention (a non-inferiority analysis).
Especially in ASPs targeted at the more severe patient
groups (e.g. septic patients), mortality can be an important
outcome. For less severe infections (e.g. urinary tract infec-
tions [UTI]), the use of mortality as an outcome measure
might be less informative. Length of stay (LOS), (secondary)
infection rates, and readmission rates are also often mea-
sured and evaluated [8,9]. Other less frequently studied
outcomes are toxicity and possible side effects (e.g. cathe-
ter-related infections or phlebitis) (see Table 1). LOS is one
of the more accessible variables to obtain. It is, however,
important to take possible secular trends toward earlier
discharge into account when evaluating an ASP in a case-
cohort setting, especially if the time-period spans multiple
years (e.g. did the institution in general saw a drop in LOS
over time). Besides the overall hospital LOS, ward-specific
LOS (such as ICU stay) is an option. The latter is of course
most interesting if the program is also ward-specifically
implemented. If treatment improves and infections are
cured more effectively, the relapse rates may decrease and
readmission rates consequently will go down. However, this
outcome measure is biased if there are other hospitals in
the vicinity where patients might be readmitted, for exam-
ple, in clusters of academic centers and surrounding general
hospitals. As a more indirect effect, the infection rate for
Clostridium difficile can be taken as an outcome measure
(see e.g. Nathwani et al., for a successful program [42]). In
some studies, a direct correlation of C. difficile infection with
antimicrobial use is suspected, especially regarding cepha-
losporins and clindamycin [43]. This rate might conse-
quently be used as an indirect indicator for antimicrobial
use and therefore as an ASP outcome measure.
Table 1. Overview of different outcome measures and some general remarks.
Outcome measures Remarks
Clinical
Mortatility Important, but less suitable for mild infections
(e.g. uncomplicated UTI)
LOS General or ward-specific (e.g. ICU stay); easy to obtain,
but highly sensitive to biases
Complications Complications such as IV catheter-related problems and
phlebitis
Clostridium difficile Also indirect measure for antimicrobial use
Readmission rates Due to relapse, but important to consider effect of
neighboring institutions
Toxicity (systemic) Most frequently in renal function and liver
Other
complications
For example, IV catheter-related thrombosis and
noninfective phlebitis
Microbiological




Total use Often measured in DDDs; however, discrepancies are
known due to generalization
IV/PO ratio Of interest with an active IV-to-PO switch program




Labor intensive and possibly subjective, but of
importance
Financial
Cost–benefit ratio Preferably done as cost-effectiveness study, including all
costs and benefits (at least at hospital level, but
preferably at societal level)
UTI: urinary tract infection; ICU: intensive care unit; PO: per os; LOS: Length of
stay; DDDs: defined daily doses; IV: intravenous.
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8. Microbiological outcome measures
Besides the important clinical outcomes (that directly impact
patient care and safety), a secondary important goal is the
reduction of resistance levels (see Table 1). There are multiple
ways to evaluate this goal. Resistance levels can be measured
as percentage of patients (or cultures) with microorganisms
‘resistant’ for a certain antibiotic compared to the number
with ‘susceptible’ microorganisms. This parameter can be
measured in infected patients or colonized patients.
Furthermore, the rate of infections with a resistant microor-
ganism can be taken as a measure (preferably as a percentage
of patients infected with the susceptible variant). Difficulties
arise due to the longer time that is required before a change
in resistance levels can be observed. In addition, reliability of
certain trends in the data is difficult to estimate when looking
at small numbers. The long time frame also implies that the
influence of possible confounders becomes greater. These
slow, subtle changes make that antibiograms have been
shown to be inconclusive as separate outcome measures and
the application of an ITS analysis is therefore a better and
preferred method for resistance measures [44]. Furthermore,
the baseline level of resistance is also of importance: countries
with high resistance levels will most likely see larger effects in
a shorter time, provided there is no major influx of resistant
microorganisms. A final complicating factor is that ‘resistant’
bacteria reside in the community and in neighboring health-
care centers. If an ASP is not implemented regionally, positive
results might not be achievable, namely at referral centers. In
this setting, a majority of the patients carrying ‘resistant’ bac-
teria will come from the surrounding health-care region
[17,45]. The quality of evidence of ASP effects on resistance
is still low [8,46]. To improve studies specifically looking at
correlating antimicrobial use and resistance development, a
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) tool was developed (STROBE-AMS)
[46]. Concerning SDD/SOD, there is still discussion regarding
possible resistance development and it is therefore highly
advisable to monitor possible resistance development when
implementing such an intervention [47].
9. Antimicrobial consumption outcome measures
ASPs mainly focus on accomplishing changes in broad spec-
trum IV prescriptions, because broad spectrum antimicrobials
are more likely to promote resistance development and IV
treatment is more likely to cause secondary infections/compli-
cations. The programs focus on either support of the prescrib-
ing physician at the start during decision making regarding
therapy, or after a few days to support the evaluation of
diagnostics and subsequent possible adjustments of therapy.
An IV-to-oral switch program is one of the most frequently
implemented interventions [48]. To measure the effect on
therapy, different outcome measures can be used (see
Table 1). Often it is chosen to quantify the antimicrobial
therapy as defined daily doses (DDDs, as defined by the
WHO), with a denominator correcting for clinical activity
such as bed days or admissions (http://www.whocc.no/atc_
ddd_index). This can be done either by looking at dispensing
data or at purchasing data, which are strongly correlated with
each other [49]. From a national point of view, a broader
denominator such as inhabitants of the health-care region is
also valuable. Because, as mentioned before, people are trans-
ferred through different health-care centers within a region,
transferring bacteria with them as well. The Infectious Diseases
Society of America and the Society for Healthcare Epidemiogy
of America advocate DDDs per 1000 patient days as universal
outcome measure for ASP programs [5]. This is, however, not
always suitable as it is a highly generalizing method that does
not take into account patient specifics (such as complicated
infections that require high-dose therapy as e.g. endocarditis)
and is known to overestimate the use [50]. With respect to
pediatric populations, these outcomes are far from optimal,
because they are based on adult dosages. This should be
taken into account, although up to now it is unclear what
measure should preferably be used instead of DDDs [51]. It
should thus be noted that a change in DDDs is not entirely
suitable for drawing conclusions on the success of an ASP.
Optimal antibiotic therapy can also mean that undertreated
patients should receive more antibiotics (e.g. deep-seated
infections or overweight patients). Personalized therapy mea-
sures such as prescribed daily doses (PDDs) or recommended
daily doses (RDD) are a more patient-specific approach to
quantify antimicrobial treatment and might give more suitable
results [50,52]. Furthermore, the length of the therapy (in days)
can be evaluated (duration of therapy [DOT]). A discrepancy
when compared to DDDs is known due to the difference
between administered dose and the WHO DDD values [53].
Because an ASP focuses on optimizing therapy, often by pro-
moting narrow spectrum oral medication, it can be worth-
while evaluating effects of these interventions specifically.
This can be done by looking at the percentage of IV medica-
tion versus oral (in DDDs/PDDs/RDDs or DOTs) and/or the
percentage broad versus narrow spectrum antibiotics (in
DDDs/PDDs/RDDs or DOTs). If it is expected that improve-
ments on a ward will be more systemic of nature, it is also
worthwhile to evaluate the percentage of patients receiving
antimicrobial therapy. Finally, appropriateness of therapy can
be evaluated. This is a more labor intensive method, while it
often requires reviewing single patient’s files, making it also
less objective than ‘hard numbers’ such as DDDs [54].
However, because the goal of an ASP is optimal therapy
(according to protocol), appropriateness of therapy is an out-
come measure that directly evaluates the main goal of the
intervention. An example of this is the analysis with regard to
the appropriateness therapy of urinary tract infections [55].
10. Financial outcome measures
With regard to financial evaluations of an ASP, there is much
room for improvement [8,37,38]. The most notable issue is
that not all costs are taken into account, but just a subset of
costs and benefits chosen based on data availability, poten-
tially leading to other cost-effectiveness results. Obviously, for
correct interpretation of costs and benefits of a stewardship
program, it is important to take into account all costs (and
benefits) besides the obvious ones (e.g. antimicrobial costs)
[41]. Preferably, this collection of costs should be done
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prospectively with up front agreed-upon variables and para-
meters. This minimizes the chances that certain cost types are
neglected or cannot be informed. Often various types appear
not to be collected when an evaluation is performed retro-
spectively. Although highly desirable, it is not always neces-
sary or feasible to be cost saving. It is however important to
know if the intervention is the most cost-effective way to
reach the preferred outcome(s), compared to other potential
interventions or the baseline situation. If indeed it is not cost
saving, it is worthwhile to take into account a certain thresh-
old of maximum cost per outcome (i.e. cost or willingness to
pay per quality-adjusted life year, life-year saved, or other
chosen outcome) to enhance optimal allocations of budgets.
An obvious start for integrative costing is to consider all
costs that had to be made to implement the program or
intervention. This definitely includes time spent by the staff
involved, both specifically hired and those already working in
the institution. In the latter case, this formally concerns so-
called opportunity costs. Furthermore, the required infrastruc-
ture (e.g. costs for the introduction of an IT program) and
consumables (e.g. extra or new diagnostics) should be con-
sidered. In short, all resources and costs of running the pro-
gram should be included, consistently measured by
opportunity costing which reflects the alternative next-best
application of these resources and costs (applying to the
people involved in the intervention, but also maintenance
contracts for IT programs or depreciation costs of laboratory
equipment).
If implementation and daily execution costs are known, one
can relate these possible savings or benefits and draw conclu-
sions on the cost-efficiency or cost-effectiveness. Preferably, all
outcome measures that were evaluated clinically are quanti-
fied and transformed into monetary and/or utility values. In
general, this will include LOS, antimicrobial use, other proce-
dures done to treat patients (including nursing time), changes
in readmissions, infections, and other complications.
Quantification into monetary values can be open to interpre-
tation and, for example for LOS high variations in willingness
to pay were shown [56], meaning that proper justification is
important, inclusive inspection of guidelines for pharmacoe-
conomic research (http://www.ispor.org).
For ASPs, costs are usually calculated from a hospital per-
spective regarding monetary outcomes and related to survival
and quality-of-life as humanities’ outcomes. When taking a
societal perspective, other outcomes should also be included,
for example costs due to reduced labor productivity [27].
Unfortunately, ASP evaluations that include financial out-
comes often only include direct antimicrobial costs within a
very limited perspective, making it nearly impossible to draw
conclusions from current literature on full cost-effectiveness of
ASPs and hampering comparison with cost-effectiveness of
other interventions in health care that are often done from
this societal perspective (e.g. drugs) [8,37,38].
11. Expert commentary
ASPs are an important topic with hundreds of publications
appearing yearly. In the last few years, asides numerous stu-
dies focusing on antibiotics, many studies were published on
antifungals with a comparable setup as antibiotic stewardship
studies and thus also comparable quality issues [57–59].
Because ASPs are consisting of multiple interventions and
not every health-care center is implementing the same inter-
ventions, outcome evaluations are also highly diverse. In this
respect, a maturity model can for example help to establish
the current status of an ASP [60]. This complexity is further
increased by the method of evaluation (e.g. RCT, ITS, or case-
control study) and different outcome measures used. Finally,
there are multiple challenges to obtain high-quality data on
effectiveness of an ASP, for example a lack of data of pre-
sumptive diagnosis at time of prescribing (or not prescribing)
antimicrobials (and subsequent evaluation of appropriate-
ness), as well as exact timing of diagnostics versus start of
therapy. Comparing and interpreting different ASP studies is
therefore extremely challenging. Cleary, there is a need for
appropriate and well-standardized definitions of interventions
of an ASP, of the preferred method of evaluation, and of the
preferred outcome measures, inclusive those from the finan-
cial–economic perspective. Until then, authors should clearly
explain and discuss their methods of evaluation in order to
make the field of ASPs more transparent.
12. Five-year view
Within the foreseeable future, more tools will be available
within daily practice to guide antimicrobial therapy in the
best possible way. Faster diagnostics, genomic data, and smar-
ter clinical decision support systems are some of these exam-
ples, as well as the growing importance of regional health-care
networks and integrative, interdisciplinary collaboration
between specialists. This entails that ASPs will continue to
develop and that interventions are expected to become easier
to implement. Such developments also impact the evaluations
of ASPs. It is therefore even more important that ASP evalua-
tions will be performed in a transparent and comparable
manner to help streamline the development process.
13. Key issues
● Antimicrobial resistance is continuing to grow and should
be considered a global threat for worldwide public health,
both from the humanistic and economic perspectives.
● Antimicrobial Stewardship Programs can improve patient
care and play an important role in counteracting the threat
of resistance.
● It is, however, vital to implement such a program in close
collaboration with other healthcare providers from the
same healthcare region and with the correct diagnostics
and infection control measures in place.
● ASPs consist of many different interventions, depending on
local settings. An ASP is therefore often a bundle of inter-
ventions, complicating formal evaluation.
● Multiple methods are available for evaluation, inclusive
those from the financial-economic perspective.
● Evaluations should be done transparently and with clear
description of all relevant aspect to facilitate comparisons
between different studies.
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